Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 100/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN PATIENTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG ACTING ß2 AGONISTS
Brief Summary: The purpose of this study is to evaluate the superiority of CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronum bromide) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate), in terms of lung functions parameters and rate of exacerbations, as well as to assess its safety and some health economics outcomes.


Options:
A: Arm Label: Tiotropium Respimat (low dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Tiotropium Respimat (high dose); Type: EXPERIMENTAL; Interventions: Drug: Tiotropium Respimat | Arm Label: Placebo Respimat; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (high dose) | Intervention Type: DRUG; Name: Placebo Respimat; Assigned to Arm(s): Placebo Respimat | Intervention Type: DRUG; Name: Tiotropium Respimat; Assigned to Arm(s): Tiotropium Respimat (low dose)
B: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol
C: Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X
D: Arm Label: CHF 5993 100/6/12.5 µg; Type: EXPERIMENTAL; Interventions: Drug: CHF 5993 100/6/12.5 µg | Arm Label: CHF 1535 100/6 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHF 1535 100/6 µg | Intervention Type: DRUG; Name: CHF 5993 100/6/12.5 µg; Assigned to Arm(s): CHF 5993 100/6/12.5 µg | Intervention Type: DRUG; Name: CHF 1535 100/6 µg; Assigned to Arm(s): CHF 1535 100/6 µg

Answer: D